Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

From Secarna Pharmaceuticals 29 May 2024

Changing the landscape of R&D to build clinical success from the ground up

In this interview, NewsMedical talks to Amanda Jones at Revvity about the strategies and solutions available to revolutionize the landscape of R&D in clinical research.

From Revvity 28 May 2024

Phase 1 trial for EBC-129 progresses into dose expansion

The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.

24 May 2024

Non-hormonal sperm-specific approach offers a promising option for reversible male contraception

The world's population has increased by more than 2.6-fold in the last 60 years. The growing trend continues – projections indicate that the number of people living on our planet will grow to 9 billion by 2037 from 8 billion in 2022.

23 May 2024

Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

Leadership from clinical stage artificial intelligence (AI)-powered drug discovery company Insilico Medicine ("Insilico") will attend the BIO International Convention in San Diego June 3-6 and present on key issues facing AI drug discovery.

23 May 2024

Breakthrough study reveals molecular drivers of Alzheimer's progression

According to the US Centers for Disease Control and Prevention, at least 5.8 million Americans are currently living with Alzheimer's disease, which is the most common form of dementia.

23 May 2024

New drug-like molecules show promise in preventing influenza by blocking virus entry

Currently available flu medications only target the virus after it has already established an infection, but what if a drug could prevent infection in the first place?

21 May 2024

Novel therapy reprograms immune cells, shrinks prostate and bladder cancers in animal study

A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.

21 May 2024

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

From ERS Genomics 21 May 2024

New CRISPR screen method reveals cellular drivers of neurological disorders

The brain is often referred to as a "black box"-;one that's difficult to peer inside and determine what's happening at any given moment.

20 May 2024

World's first human mini-brain with a fully functional blood-brain barrier developed

In a pioneering achievement, a research team led by experts at Cincinnati Children's have developed the world's first human mini-brain that incorporates a fully functional blood-brain barrier (BBB).

20 May 2024

Insilico and NVIDIA unveil new LLM transformer for solving biological and chemical tasks

In a new paper, researchers from clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine ("Insilico"), in collaboration with NVIDIA, present a new large language model (LLM) transformer for solving biological and chemical tasks called nach0.

20 May 2024

Cancer researchers urged to embrace AI for groundbreaking insights and efficiency

A review in Nature Reviews Cancer emphasizes the necessity for cancer researchers to understand AI's potentials and limitations, detailing its applications and challenges in cancer research to aid non-computational biologists.

20 May 2024

AlphaFold2 can be an effective tool in structure-based drug discovery

One of the most consequential advances in artificial intelligence isn't an eerily conversational chatbot-;it's a new way to unpack the unique 3D structures of proteins.

17 May 2024

Innovative DL4MicEverywhere platform revolutionizes microscopy image analysis with AI

A team of researchers from the Instituto Gulbenkian de Ciência (IGC) in Portugal, together with Åbo Akademi University in Finland, the AI4Life consortium, and other collaborators, have developed an innovative open-source platform called DL4MicEverywhere published today in the journal Nature Methods.

17 May 2024

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

RedShiftBio, a leader in innovative biophysical characterization and bioprocess analytical solutions, proudly announces the launch of Aurora TX at The Protein & Antibody Engineering Summit (PEGS), kicking off on May 13, 2024, in Boston, MA. Aurora TX is the company's latest, most advanced instrument featuring ground-breaking MMS technology, and sets a new standard in biomolecular analysis by providing ultra-sensitive, ultra-precise measurements of biomolecule structure and stability, now enhanced with the addition of thermal ramping capability.

From RedShiftBio 16 May 2024

Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO.

From Enhanc3D Genomics 15 May 2024

Drug Discovery News and Research

Further Reading

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Changing the landscape of R&D to build clinical success from the ground up

Phase 1 trial for EBC-129 progresses into dose expansion

Non-hormonal sperm-specific approach offers a promising option for reversible male contraception

Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

Breakthrough study reveals molecular drivers of Alzheimer's progression

New drug-like molecules show promise in preventing influenza by blocking virus entry

Novel therapy reprograms immune cells, shrinks prostate and bladder cancers in animal study

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

New CRISPR screen method reveals cellular drivers of neurological disorders

World's first human mini-brain with a fully functional blood-brain barrier developed

Insilico and NVIDIA unveil new LLM transformer for solving biological and chemical tasks

Cancer researchers urged to embrace AI for groundbreaking insights and efficiency

AlphaFold2 can be an effective tool in structure-based drug discovery

Innovative DL4MicEverywhere platform revolutionizes microscopy image analysis with AI

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer

Optibrium partners with FMC Corporation to transform agrochemical discovery

Sapio Sciences Unveils Enhanced Molecular Biology Toolkit

New diagnostic and treatment approach could revolutionize bladder cancer care

Drug Discovery - Second Edition eBook

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Latest Life Science News